![]() “The acquisition of Millipore in 2010 was the first major step in that journey and with the completion of the Sigma-Aldrich acquisition, we will take a quantum leap toward securing our competitive position in that space.” “This is a significant milestone in our long-term strategy to invest in life science,” said Bernd Reckmann, Member of the Executive Board in charge of the company’s Life Science and Performance Materials business sectors. The company will cover every step of the biotech production chain, creating a complete end-to-end workflow with enhanced customer service, a simplified customer interface and a leading distribution platform. With the acquisition of Sigma-Aldrich, Merck KGaA, Darmstadt, Germany, will be able to serve life science customers around the world with a highly attractive set of established brands such as SAFC and BioReliance, in addition to Millipore and Milli-Q, as well as an efficient supply chain that can support the delivery of more than 300,000 products. Merck KGaA, Darmstadt, Germany, has made acquisitions and divestments totalling € 38 billion in the past decade, turning the former pharma and chemicals company into a science and technology company with three businesses in healthcare, life science and performance materials that serve as platforms to compete in their markets and drive innovations in these industries. “We’re now a leading player in the $ 130 billion global life science industry and together with our two other growth platforms Healthcare and Performance Materials, we are set to tackle global challenges that will fundamentally change the world in which we live.” ![]() “The acquisition of Sigma-Aldrich marks the culmination of almost a decade of transformation, further affirming we are a leading science and technology company,” said Karl-Ludwig Kley, CEO and Chairman of Merck KGaA, Darmstadt, Germany. As announced on publication of the results for the third quarter of 2015 on November 12, the company expects sales to amount to between € 12.6 billion and € 12.8 billion in 2015. Combined pro forma full-year life science sales amounted to € 4.6 billion in 2014. Following the acquisition, Merck KGaA, Darmstadt, Germany, will have around 50,000 employees in 67 countries, working at 72 manufacturing sites worldwide. The completion follows last week’s approval from the European Commission, which was the final antitrust condition required to close the Sigma-Aldrich transaction. Organizational structure and senior management team in placeĭarmstadt, Germany, NovemMerck KGaA, Darmstadt, Germany, a leading science and technology company, today announced the completion of its $ 17 billion acquisition of Sigma-Aldrich, creating one of the leaders in the $ 130 billion global industry to help solve the toughest problems in life science.Customers benefit from a more than 300,000-product offering with highly-respected brands distributed through leading life science e-commerce and distribution platform.New entity to enhance product range, capabilities and geographic reach.$ 17 billion acquisition establishes leading player in life science industry.With this marriage of broad capabilities and resources, annual double-digit sales growth became the standard in the 1980s and 1990s, with significant expansion in facilities, acquisitions and ventures into new market sectors.Merck KGaA, Darmstadt, Germany, Completes Sigma-Aldrich Acquisition in 1975, forming Sigma-Aldrich Corporation. When changing trends in chemical research confirmed the synergy to be realized from their complementary product offerings, Aldrich Chemical Co. For many years, the two companies grew independently, Sigma serving primarily biochemists and Aldrich serving organic chemists. Both companies started with the production and distribution of a single proprietary chemical: Adenosine triphosphate (ATP) by Sigma and 1-methyl-3- nitro-1-nitrosoguanidine (MNNG) by Aldrich. Sigma and Aldrich were founded separately in 19, respectively, to supply biochemicals and chemicals to research scientists in the U.S. Today, Merck is a global pharmaceutical, chemical and life science company with a history that began in 1668 and a future shaped by approximately 50,000 employees in 66 countries.įor the full history, click here. New ultrapure products were sold the first biotechnology production process was introduced and Merck entered the market. As the century progressed, so did the company. The transformation of Merck to a research-driven industrial company was marked in 1827 when Emanuel Merck isolated and characterized alkaloids for distribution to chemists. In 1668, Friedrich Jacob Merck purchased the Engel Pharmacy in Darmstadt, Germany.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |